Virginia Retirement Systems Et Al Puma Biotechnology, Inc. Transaction History

Virginia Retirement Systems Et Al

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$2.85 - $6.58 $243,960 - $563,248	-85,600 Closed	0 $0
Q3 2021 Oct 21, 2021	BUY	$6.63 - $9.39 $94,809 - $134,277	14,300 Added 20.06%	85,600 $600,000
Q2 2021 Aug 13, 2021	SELL	$8.98 - $11.6 $11,674 - $15,080	-1,300 Reduced 1.79%	71,300 $655,000
Q1 2021 Apr 30, 2021	BUY	$9.38 - $13.63 $140,700 - $204,450	15,000 Added 26.04%	72,600 $706,000
Q4 2020 Feb 16, 2021	BUY	$7.78 - $12.13 $24,896 - $38,816	3,200 Added 5.88%	57,600 $591,000
Q3 2020 Nov 12, 2020	SELL	$9.5 - $11.14 $14,250 - $16,710	-1,500 Reduced 2.68%	54,400 $549,000
Q2 2020 Aug 12, 2020	BUY	$7.01 - $13.24 $316,151 - $597,124	45,100 Added 417.59%	55,900 $583,000
Q1 2020 May 12, 2020	BUY	$6.28 - $14.57 $67,824 - $157,356	10,800 New	10,800 $91,000
Q4 2018 Feb 07, 2019	SELL	$20.07 - $46.7 $453,582 - $1.06 Million	-22,600 Closed	0 $0
Q2 2018 Aug 03, 2018	BUY	$48.3 - $68.25 $1.09 Million - $1.54 Million	22,600 New	22,600 $1.34 Million

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $128M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

Stay updated on Virginia Retirement Systems Et Al with notifications on news.